skytrofa (previously lonapegsomatropin ascendis pharma)
ascendis pharma endocrinology division a/s - lonapegsomatropin - growth and development - hormonas e análises pituitárias e hipotalâmicas - growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion (growth hormone deficiency [ghd]),.
raptiva
serono europe limited - efalizumab - psoríase - imunossupressores - tratamento de pacientes adultos com psoríase em placas crônica moderada a grave que não responderam ou que têm uma contra-indicação ou são intolerantes a outras terapias sistêmicas, incluindo ciclosporina, metotrexato e puva (ver seção 5. 1 - eficácia clínica).
vaxchora
bavarian nordic a/s - o vibrio cholerae, tensão dcv 103-hgr, ao vivo - cólera - vacinas - vaxchora is indicated for active immunisation against disease caused by vibrio cholerae serogroup o1 in adults and children aged 2 years and older. esta vacina deve ser utilizado em conformidade com as recomendações oficiais.
imbruvica
janssen-cilag farmacÊutica ltda - ibrutinibe - agentes antineoplÁsicos
imvanex
bavarian nordic a/s - vacina modificada ankara - vírus nórdico bávaro (mva-bn) - smallpox vaccine; monkeypox virus - outras vacinas virais, - active immunisation against smallpox, monkeypox and disease caused by vaccinia virus in adults (see sections 4. 4 e 5. o uso desta vacina deve ser de acordo com as recomendações oficiais.
trimedal
glaxosmithkline brasil ltda - cloridrato de fenilefrina, maleato de dimetindeno, paracetamol, rutosÍdeo, Ácido ascÓrbico - produto p.terapia sintomatica da gripe
trimedal
novartis biociencias s.a - produto p.terapia sintomatica da gripe
oxy anios 5
laboratoires anios, s.a - peróxido de hidrogénio; Ácido peracético - solução - pt 4 - alimentação e área de alimentação - peróxido de hidrogénio, Ácido peracético
purevax rcp
boehringer ingelheim vetmedica gmbh - attenuated feline panleucopenia virus (pli iv) - imunológicos para felidae, - gatos - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs. onset of immunity is one week after primary vaccination course the duration of immunity is one year after the primary vaccination course and three years after the last re-vaccination.
purevax rcp felv
boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - imunológicos para felidae, - gatos - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.